{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:19:22Z","timestamp":1781630362902,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Japan Agency for Medical Research and Development Fund","award":["18ck0106349h0002"],"award-info":[{"award-number":["18ck0106349h0002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00277-019-03853-1","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T03:34:40Z","timestamp":1590464080000},"page":"2141-2148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7251-7920","authenticated-orcid":false,"given":"Akiko Miyagi","family":"Maeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayako","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"3853_CR1","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1056\/NEJMct1114348","volume":"366","author":"DG Maloney","year":"2006","unstructured":"Maloney DG (2006) Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366:2008\u20132016","journal-title":"N Engl J Med"},{"key":"3853_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.2008.001628","volume":"95","author":"SH Lim","year":"2010","unstructured":"Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95:135\u2013143","journal-title":"Haematologica"},{"key":"3853_CR3","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"3853_CR4","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol 15:3266\u20133274","journal-title":"J Clin Oncol"},{"key":"3853_CR5","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1182\/blood-2006-04-014639","volume":"108","author":"M Binder","year":"2006","unstructured":"Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M (2006) The epitope recognized by rituximab. Blood 108:1975\u20131978","journal-title":"Blood"},{"key":"3853_CR6","first-page":"1215","volume":"136","author":"DY Mason","year":"1990","unstructured":"Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen J (1990) Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 136:1215\u20131222","journal-title":"Am J Pathol"},{"key":"3853_CR7","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","volume":"113","author":"J Hiraga","year":"2009","unstructured":"Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113:4885\u20134893","journal-title":"Blood"},{"key":"3853_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbrc.2009.09.059","volume":"390","author":"T Sugimoto","year":"2009","unstructured":"Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, Naoe T (2009) Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 390:48\u201353","journal-title":"Biochem Biophys Res Commun"},{"key":"3853_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1600-0609.2012.01838.x","volume":"89","author":"T Nakamaki","year":"2012","unstructured":"Nakamaki T, Fukuchi K, Nakashima H, Ariizumi H, Maeda T, Saito B, Yanagisawa K, Tomoyasu S, Homma M, Shiozawa E, Yamochi-Onizuka T, Ota H (2012) CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma. Eur J Haematol 89:350\u2013355","journal-title":"Eur J Haematol"},{"key":"3853_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1349-7006.2008.01005.x","volume":"100","author":"AM Maeshima","year":"2009","unstructured":"Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y (2009) Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin\u2019s lymphoma after rituximab therapy. Cancer Sci 100:54\u201361","journal-title":"Cancer Sci"},{"key":"3853_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3324\/haematol.2008.001024","volume":"94","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Leach S, Woolcock B et al (2009) CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 94:423\u2013427","journal-title":"Haematologica"},{"key":"3853_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","volume":"119","author":"GA Kennedy","year":"2002","unstructured":"Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill D (2002) Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 119:412\u2013416","journal-title":"Br J Haematol"},{"key":"3853_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/PAS.0b013e3182759008","volume":"37","author":"AM Maeshima","year":"2013","unstructured":"Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H (2013) Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Am J Surg Pathol 37:563\u2013570","journal-title":"Am J Surg Pathol"},{"key":"3853_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00277-003-0694-1","volume":"82","author":"TA Alovaro-Naranjo","year":"2003","unstructured":"Alovaro-Naranjo TA, Jaen-Martinez JJ, Guma-Padro JG et al (2003) CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol 82:585\u2013588","journal-title":"Ann Hematol"},{"key":"3853_CR15","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1080\/10428190500178399","volume":"46","author":"S Woehrer","year":"2005","unstructured":"Woehrer S, Streubel B, Chott A, Hoffmann M, Raderer M (2005) Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma 46:1645\u20131649","journal-title":"Leuk Lymphoma"},{"key":"3853_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/039463200601900218","volume":"19","author":"G Goteri","year":"2006","unstructured":"Goteri G, Olivieri A, Ranaldi M et al (2006) Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients\u2019 outcome. Int J Immunopathol Pharmacol 19:421\u2013431","journal-title":"Int J Immunopathol Pharmacol"},{"key":"3853_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1097\/01.pas.0000169496.04283.b9","volume":"29","author":"L Pijuan","year":"2005","unstructured":"Pijuan L, Vicioso L, Bellosillo B, Ferrer MD, Bar\u00f3 T, Pedro C, Lloreta-Trull J, Munn\u00e9 A, Serrano S (2005) CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin\u2019s lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. Am J Surg Pathol 29:1399\u20131403","journal-title":"Am J Surg Pathol"},{"key":"3853_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"3853_CR19","unstructured":"Swerdlow SH, Campo E, Harris NL, et al (2017) eds. WHO classification of tumours of haematopoietic and lymphoid tissues: IARC, Lyon."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03853-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-019-03853-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03853-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:20:36Z","timestamp":1621984836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-019-03853-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["3853"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03853-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"15 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}